...
首页> 外文期刊>British Journal of Cancer >Clinical testing of the radiosensitizer Ro 07-0582: Experience with multiple doses
【24h】

Clinical testing of the radiosensitizer Ro 07-0582: Experience with multiple doses

机译:Ro 07-0582放射增敏剂的临床测试:多次给药的经验

获取原文

摘要

The hypoxic cell radiosensitizer, Ro 07-0582, has now been given in multiple doses to 16 patients. They have received a total of 15-51 g in 3-20 doses. Immediate tolerance was good, and satisfactory plasma levels of the drug were consistently obtained. Neurotoxicity was, however, troublesome: convulsions occurred in the patient given the highest dose, and there was peripheral neuropathy in 11 cases. Tumour concentrations similar to those in plasma were obtained in human tumours, in contrast to the findings in mouse tumours where concentrations are usually below 40% of plasma levels. In the treatment of human tumours, a lower dose of Ro 07-0582 should give useful hypoxic cell sensitization. Although the total dose of Ro 07-0582 must be limited, there is a real prospect that it will give benefit in clinical radiotherapy.
机译:缺氧细胞放射增敏剂Ro 07-0582现在已向16例患者多次给药。他们共接受了15到51克(3到20剂)的剂量。即时耐受性良好,并始终获得令人满意的药物血浆水平。然而,神经毒性是麻烦的:给予最高剂量的患者发生惊厥,11例出现周围神经病变。在人肿瘤中获得的血浆浓度与血浆中的浓度相似,而小鼠肿瘤中的浓度通常低于血浆水平的40%。在人类肿瘤的治疗中,较低剂量的Ro 07-0582应该会产生有用的低氧细胞致敏作用。尽管必须限制Ro 07-0582的总剂量,但确实有希望在临床放疗中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号